Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. JANX
stocks logo

JANX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.659
+83.08%
--
--
-0.707
+85.97%
--
--
-0.753
+36.97%
Estimates Revision
The market is revising Upward the revenue expectations for Janux Therapeutics, Inc. (JANX) for FY2025, with the revenue forecasts being adjusted by 225% over the past three months. During the same period, the stock price has changed by -31.61%.
Revenue Estimates for FY2025
Revise Upward
up Image
+225%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-8.94%
In Past 3 Month
Stock Price
Go Down
down Image
-31.61%
In Past 3 Month
Wall Street analysts forecast JANX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JANX is 77.09 USD with a low forecast of 42.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast JANX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JANX is 77.09 USD with a low forecast of 42.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 16.400
sliders
Low
42.00
Averages
77.09
High
200.00
Current: 16.400
sliders
Low
42.00
Averages
77.09
High
200.00
Stifel
Stephen Willey
Buy
downgrade
$46 -> $38
2025-12-02
New
Reason
Stifel
Stephen Willey
Price Target
$46 -> $38
2025-12-02
New
downgrade
Buy
Reason
Stifel analyst Stephen Willey lowered the firm's price target on Janux Therapeutics to $38 from $46 and keeps a Buy rating on the shares. The firm sees "some positives to extract" from Monday's JANX007 Phase 1 update, but also questions, the analyst tells investors. While acknowledging the near-term catalyst calendar "doesn't set-up great," the firm adds that it "struggles to rationalize" the 40% post-close attrition in shares given "platform validation in a thematically/strategically space."
Cantor Fitzgerald
Josh Schimmer
Overweight
downgrade
$200 -> $150
2025-12-02
New
Reason
Cantor Fitzgerald
Josh Schimmer
Price Target
$200 -> $150
2025-12-02
New
downgrade
Overweight
Reason
Cantor Fitzgerald analyst Josh Schimmer lowered the firm's price target on Janux Therapeutics to $150 from $200 and keeps an Overweight rating on the shares. The new data for JANX007 addresses a number of key important questions, but also leaves a handful of remaining variables and blanks to fill in, and doesn't provide timelines for next clinical or regulatory updates, the analyst tells investors in a research note. Still, Cantor thinks the selloff is overdone, setting up for a compelling entry point.
Clear Street
Buy
downgrade
$80 -> $32
2025-12-02
New
Reason
Clear Street
Price Target
$80 -> $32
2025-12-02
New
downgrade
Buy
Reason
Clear Street lowered the firm's price target on Janux Therapeutics to $32 from $80 and keeps a Buy rating on the shares. The firm cites "more pragmatic" market entry timelines for the target cut. It views the updated Phase 1 data for JANX007 as highlighting a "thoughtful development process."
H.C. Wainwright
Buy
to
Buy
downgrade
$70 -> $45
2025-12-02
New
Reason
H.C. Wainwright
Price Target
$70 -> $45
2025-12-02
New
downgrade
Buy
to
Buy
Reason
H.C. Wainwright lowered the firm's price target on Janux Therapeutics to $45 from $70 and keeps a Buy rating on the shares after the company announced updated interim results from its ongoing Phase 1 study evaluating JANX007 in metastatic castration-resistant prostate cancer. The overall efficacy profile deteriorated on key endpoints, the analyst tells investors in a research note. H.C. Wainwright believes the JANX007 update "were mixed," and feels the drug will likely be a "show me" story until the dataset matures.
BofA
Buy
downgrade
$58 -> $49
2025-12-02
New
Reason
BofA
Price Target
$58 -> $49
2025-12-02
New
downgrade
Buy
Reason
BofA lowered the firm's price target on Janux Therapeutics to $49 from $58 and keeps a Buy rating on the shares after the company announced updated interim data for JANX007 from the Phase 1 clinical program in patients with mCRPC. The firm still thinks '007 is "a viable drug with a reasonable safety profile and the potential to show a benefit in OS over Pluvicto," says the analyst, who views the 43% move lower in shares as "overdone" despite calling the latest Phase 1 update "admittedly mixed." The firm lowers its price target as it pushes back expectations for a JANX007 launch to 2028 and reduces its peak market share estimate to 15% from 20%.
Wolfe Research
Peer Perform
initiated
2025-11-17
Reason
Wolfe Research
Price Target
2025-11-17
initiated
Peer Perform
Reason
Wolfe Research initiated coverage of Janux Therapeutics with a Peer Perform rating and no price target. The firm believes additional work may be needed on JANX-007 before strong durability data materialize, the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Janux Therapeutics Inc (JANX.O) is -5.69, compared to its 5-year average forward P/E of -15.54. For a more detailed relative valuation and DCF analysis to assess Janux Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-15.54
Current PE
-5.69
Overvalued PE
-4.43
Undervalued PE
-26.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-8.23
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.42
Undervalued EV/EBITDA
-16.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
506.26
Current PS
0.00
Overvalued PS
958.98
Undervalued PS
53.55
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 575.67% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

JANX News & Events

Events Timeline

(ET)
2025-12-02
21:30:00
Bitcoin Rebounds Supporting Market Stabilization; Multiple Companies Release Earnings
select
2025-12-02
12:11:00
Banco Santander Sells 3.5% Stake in Santander Bank Polska for $473.1M
select
link
2025-12-02
12:11:00
Janux Therapeutics Shares Plunge 48.4% to $17.52
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-02Benzinga
PinnedJanux Therapeutics Shares Reach 52-Week Low Following Trial Announcement

  • Stock Performance: Janux Therapeutics Inc. (NASDAQ: JANX) experienced a significant drop in stock price, hitting a 52-week low after releasing interim data for its JANX007 Phase 1 program targeting metastatic castration-resistant prostate cancer (mCRPC).

  • Clinical Trial Results: The Phase 1 trials showed promising results with high prostate-specific antigen (PSA) response rates and confirmed partial responses in 30% of evaluable patients, alongside a manageable safety profile primarily involving grade 1 and 2 cytokine release syndrome (CRS).

  • Development Strategy: Janux is focusing on advancing JANX007 as a monotherapy and in combination with darolutamide for taxane-naïve mCRPC patients, while also considering evaluation in PARP inhibitor-refractory patients for expedited approval.

  • Analyst Insights: Analysts from William Blair view the stock's decline as an overreaction and see potential in JANX007, suggesting that upcoming updates from the Phase Ib trial in 2026 could restore investor confidence, with some recommending the current sell-off as a buying opportunity.

[object Object]
Preview
5.0
12-04NASDAQ.COM
Janux Executive Sells 16,665 Shares for $501,000 Through Options Exercise

  • Insider Transaction Details: Meyer Andrew Hollman, Chief Business Officer at Janux Therapeutics, exercised 16,665 stock options and sold the shares for approximately $501,000 on October 28, 2025, representing 16.87% of his direct holdings prior to the transaction.

  • Nature of the Transaction: This was a routine "exercise-and-sell" maneuver, allowing Hollman to cover tax liabilities from the option exercise while locking in profits, without altering his net equity stake in the company.

  • Post-Transaction Holdings: After the sale, Hollman retains 82,139 shares valued at around $2.44 million, indicating a significant ongoing investment in Janux Therapeutics.

  • Market Context and Risks: Janux Therapeutics operates in a volatile biotech sector, with stock prices susceptible to dramatic changes based on clinical trial results, highlighting the risks for investors in such companies.

[object Object]
Preview
4.0
12-03NASDAQ.COM
Stifel Continues to Recommend Buy for Janux Therapeutics (JANX)

  • Analyst Recommendation: Stifel has maintained a Buy recommendation for Janux Therapeutics, with an average one-year price target of $77.76/share, indicating a potential upside of 128.77% from its current price of $33.99/share.

  • Fund Sentiment: There are 398 funds reporting positions in Janux Therapeutics, with a slight decrease in ownership by 5.24% over the last quarter, while the average portfolio weight has increased by 10.67%.

  • Shareholder Activity: Significant shareholders like Ra Capital Management and Janus Henderson Group have increased their holdings in Janux Therapeutics, with Janus Henderson raising its allocation by 3.94% over the last quarter.

  • Market Outlook: The put/call ratio for Janux Therapeutics is 0.36, suggesting a bullish sentiment among investors, despite a projected annual revenue decrease of 83% and a non-GAAP EPS of -1.83.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Janux Therapeutics Inc (JANX) stock price today?

The current price of JANX is 16.4 USD — it has decreased -4.15 % in the last trading day.

arrow icon

What is Janux Therapeutics Inc (JANX)'s business?

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

arrow icon

What is the price predicton of JANX Stock?

Wall Street analysts forecast JANX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JANX is 77.09 USD with a low forecast of 42.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Janux Therapeutics Inc (JANX)'s revenue for the last quarter?

Janux Therapeutics Inc revenue for the last quarter amounts to 10.00M USD, increased 2177.90 % YoY.

arrow icon

What is Janux Therapeutics Inc (JANX)'s earnings per share (EPS) for the last quarter?

Janux Therapeutics Inc. EPS for the last quarter amounts to -0.39 USD, decreased -23.53 % YoY.

arrow icon

What changes have occurred in the market's expectations for Janux Therapeutics Inc (JANX)'s fundamentals?

The market is revising Upward the revenue expectations for Janux Therapeutics, Inc. (JANX) for FY2025, with the revenue forecasts being adjusted by 225% over the past three months. During the same period, the stock price has changed by -31.61%.
arrow icon

How many employees does Janux Therapeutics Inc (JANX). have?

Janux Therapeutics Inc (JANX) has 74 emplpoyees as of December 05 2025.

arrow icon

What is Janux Therapeutics Inc (JANX) market cap?

Today JANX has the market capitalization of 986.42M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free